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Background. Patients with multiple recurrent Clostridioides difficile infections (rCDI) are treated with fecal microbiota trans-
plantation (FMT), using feces provided by healthy donors. Blastocystis colonization of donors is considered an exclusion criterion, 
whereas its pathogenicity is still under debate.
Methods. The introduction of molecular screening for Blastocystis sp. at our stool bank identified 2 donors with prior negative 
microscopies but positive polymerase chain reactions (PCRs). Potential transmission of Blastocystis sp. to patients was assessed on 
16 fecal patient samples, pre- and post-FMT, by PCR and subtype (ST) analyses. In addition, clinical outcomes for the treatment of 
rCDI (n = 31), as well as the development of gastrointestinal symptoms, were assessed.
Results. There was 1 donor who carried Blastocystis ST1, and the other contained ST3. All patients tested negative for 
Blastocystis prior to FMT. With a median diagnosis at 20.5 days after FMT, 8 of 16 (50%) patients developed intestinal colonization 
with Blastocystis, with identical ST sequences as their respective donors. Blastocystis-containing fecal suspensions were used to treat 
31 rCDI patients, with an FMT success rate of 84%. This success rate was not statistically different from patients transferred with 
Blastocystis sp.–negative donor feces (93%, 76/82). Patients transferred with Blastocystis sp.–positive donor feces did not report any 
significant differences in bowel complaints in the first week, after 3 weeks, or in the months following FMT.
Conclusions. We demonstrated the first transmission of Blastocystis ST1 and ST3 from donors to patients by FMT. This did not 
result in gastrointestinal symptomatology or have any significant effect on rCDI treatment outcomes.
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Blastocystis is a genus of a common unicellular intestinal para-
site in humans and animals that belongs to the stramenopiles, 1 
of the 8 major phylogenetic groups of eukaryotes. It is a diverse 
genus comprising 17 characterized lineages: the so-called sub-
types (ST1 – ST17), of which 9 have been reported to occur in 
the human gastrointestinal tract [1, 2]. Blastocystis sp. carriage 
is very common but varies globally, from 0.5% in Japan to 100% 
in Senegal and 30–50% in Europe [3–6].
The pathogenicity of Blastocystis sp. is uncertain and, in ge-
neral, it is considered an innocent parasite [7]. The presumed 
entero-pathogenicity is based on anecdotal case reports and 
retrospective reviews and is mainly tested in animal models [8, 
9]. The symptoms attributed to this organism include nausea, 
anorexia, abdominal pain, flatulence, and acute or chronic di-
arrhea [8]. However, outbreaks have never been reported and 
a human challenge model has not been applied. An association 
of Blastocystis sp. with irritable bowel syndrome was suggested 
[10, 11], but could not be confirmed in 2 large cohort studies [4, 
12]. Interestingly, Blastocystis sp. is found to be less prevalent 
in patients with inflammatory bowel disease, a disorder which 
is associated with a reduced diversity of the gut microbiota [4, 
13, 14], and asymptomatic Blastocystis sp. carriers tend to have 
a more diverse microbiota [4, 15–20]. These observations could 
indicate that the presence of Blastocystis sp. may reflect a more 
healthy and diverse state of the gut microbiota.
Patients with multiple recurrent Clostridioides difficile infec-
tions (rCDIs) are treated with fecal microbiota transplantation 
(FMT), prepared with feces of healthy donors. Carriership of 
Blastocystis sp. by healthy donors is considered an exclusion 
criterion for donation by several stool banks, including the 
Netherlands Donor Feces Bank (NDFB) [21–26], resulting in 
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considerable exclusion of donors (30-50%). It is questionable 
whether this is justified. Therefore, knowledge about the po-
tential side effects and treatment success of cotransplantation 
of Blastocystis sp. with FMT is warranted. This study reports 
the cotransmission of Blastocystis sp. from donor to patient, 
and its influence on the outcomes and health of rCDI patients 
receiving FMT.
METHODS
Donors and Donor Fecal Suspensions for Fecal Microbiota Transplantation 
The NDFB is located within the Department of Medical 
Microbiology at the Leiden University Medical Center, and 
started with the treatment of patients with multiple rCDI with 
FMTs in 2016 [21]. All donors of the NDFB are healthy individ-
uals between the ages of 18 and 50, with normal weight (body 
mass index, 18.5–25) and no relevant medical history or medi-
cation use. All donors are extensively screened and rescreened 
for disorders associated with a perturbed microbiota and poten-
tial transmissible infectious diseases [21].
The NDFB uses standardized procedures for the collection, 
preparation, and storage of donor fecal suspensions, as de-
scribed previously [21]. In short, donors deliver stool at the 
NDFB within 2 hours after defecation. It takes 60 grams of donor 
feces to prepare 1 fecal suspension. The feces are homogenized 
with sterile saline with the use of a mortar and pestle, sieved, 
and centrifuged until an end volume of 200 ml (containing 10% 
glycerol). Then, 2 cc of the final fecal suspension and 2 grams of 
the original donor stool are separately aliquoted and stored as 
quality controls. The fecal suspensions are stored within 6 hours 
following defecation. Storage is accommodated by a certified, 
centralized biobanking facility in a dedicated −80°C freezer 
with connected alarm notification and biobanking information 
and management system (BIMS SampleNavigator).
Patient Selection and Treatment
Requests for FMT in rCDI patients are carefully evaluated by the 
working group of the NDFB. Upon approval, the NDFB facili-
tates FMT by providing ready-to-use fecal suspensions for treat-
ment at the local hospital, as previously described [21]. Patients 
are preferably pretreated with vancomycin (125–250 mg means 
4 times each day) for a minimum of 4 days, followed by 2 liters 
of macrogol solution (bowel lavage) 1 day prior to FMT. The 
thawed fecal suspension is slowly infused through a duodenal 
tube, or via a colonoscopy in selected patients. 
Follow-Up
The routine follow-up of patients consists of a standardized ques-
tionnaire filled out 3 weeks post-FMT by their local, treating 
physician and a telephonic interview performed by a member of 
the NDFB working group at 2 months post-FMT. For this study, 
an additional telephonic interview was performed in January 
2019, between 5 to 33  months post-FMT. In addition, treating 
physicians were asked to contact the NDFB in case of any ad-
verse events or treatment failures. Success of FMT was defined as 
the resolution of CDI symptoms without a relapse of CDI within 
2 months. A relapse of CDI was defined as the development of 
diarrhea for at least 2 consecutive days within 2 months following 
FMT, either in combination with a positive free-feces toxin test 
or polymerase chain reaction (PCR; proven relapse), or clin-
ical suspicion for CDI (probable). A CDI episode occurring at a 
later time point than 2 months post-FMT was regarded as a new 
CDI episode, as proposed by the European Society of Clinical 
Microbiology and Infectious Diseases (ESCMID) C.  difficile 
treatment guideline [27]. The development of gastrointestinal 
and other adverse events was also assessed, including nausea, 
vomiting, burping, abdominal pain, diarrhea not caused by rCDI, 
obstipation, hospital admittance, and antibiotic use, and we in-
cluded an open field for other complaints. In addition, partici-
pants were asked to evaluate their defecation pattern post-FMT, 
compared to pre-FMT (improved, similar, or deteriorated).
Stool samples of patients were collected before and approx-
imately 3 weeks after FMT. Stool samples were preserved until 
use at −80°C. Patients provided informed consent for the collec-
tion of stool samples and outcome data of FMT for research pur-
poses, which was approved by the Medical Ethics Committee at 
the Leiden University Medical Center (P15.145).
Blastocystis sp. Diagnostics and Typing
Stool samples of the donors were routinely screened for the 
presence of Blastocystis sp. by direct microscopy of the feces and 
the Ridley-Allen sedimentation method [28]. These screenings 
were performed on fresh donor stool (<2 hours after defeca-
tion). With the introduction of a specific Blastocystis PCR at 
our department in 2018, 2 donors were identified with nega-
tive microscopies but positive PCRs for Blastocystis sp. In ret-
rospect, all donated fecal samples used to treat patients were 
tested for the presence of Blastocystis sp. with a specific PCR 
targeting approximately 360 bp of the small subunit ribosomal 
RNA gene (see Supplementary Material). Positive samples were 
subtyped using a sequence analysis, as described previously 
[29]. Furthermore, 16 available pre- and post-FMT fecal sam-
ples of the patients treated by these 2 respective donors were 
tested with Blastocystis sp. PCR and, when positive, were subse-
quently subtyped. Patients and donors that were PCR positive 
for Blastocystis sp. were regarded as Blastocystis sp. colonized.
Statistics
The statistical analysis was performed using SPSS 23.0 statis-
tical software. To test for differences between the prevalence 
rates of relapses and gastrointestinal symptoms of Blastocystis 
sp.–positive versus –negative donors and patients, a Chi-square 
test or Fischer exact was performed in cases of n < 5. An odds 
ratio (OR) was calculated using logistic regression and pre-
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linear-by-linear association test was used. In addition, Kaplan-
Meier curve and log-rank tests to compare CDI-free survival 
rates between patients receiving Blastocystis sp.–positive or –
negative donor feces were performed. For statistical compari-
sons, a P value below .05 was considered statically significant.
RESULTS
Blastocystis sp.–Positive Donors
In the period between May 2016 and December 2018, 110 pa-
tients were treated with 113 FMTs, using fecal suspensions of 
10 donors. In 2 out of 10 donors, Blastocystis sp. testing re-
vealed a negative stool microcopy but, in retrospect, a positive 
PCR, with cycle quantification values ranging from 18.95 to 
25.13 (Table 1). A subtype analysis revealed that 1 donor had 
Blastocystis ST1 and the other donor had ST3. The Blastocystis 
ST1 donor carried the Blastocystis for at least 3 donating 
months, and the second donor carried the Blastocystis ST3 for 
at least 9 donating months.
Patients Treated With Blastocystis sp. Containing Fecal Microbiota 
Transplantation Suspensions
Donor feces suspensions of Blastocystis sp.–positive donors 
were used for rCDI treatment of 31 patients; 4 patients were 
treated with donor feces containing Blastocystis ST1 and 27 
with Blastocystis ST2. From 16 of 31 patients, stool samples 
pre-FMT and post-FMT were available. All fecal samples 
of the patients tested Blastocystis sp.–negative prior to FMT 
(Table 1). With a median of 20.5 days (5–53 days) post-FMT, 
8 of 16 (50%) patients developed intestinal colonization with 
Blastocystis: 7 of 14 with ST3 and 1 of 2 with ST1 (Table 1). 
Patient DNA sequences of part of the Blastocystis small subunit 
ribosomal RNA region were 100% identical to the sequences of 
their respective donors.
Patient Follow-Up for Recurrent Clostridioides difficile Infections 
Treatment
Of the 113 FMTs performed in 110 patients to cure rCDI, 31 
FMTs were performed with feces from the Blastocystis sp.–pos-
itive donors and 82 with Blastocystis sp.–negative donor feces. 
Patients treated with Blastocystis sp.–positive donor feces had 
an FMT success rate (cure without relapse <2 months) of 84% 
(26/31), whereas treatment with Blastocystis sp.–negative donor 
feces had a success rate of 93% (76/82). This difference in suc-
cess rates was not significant (Table 2; Figure 1). Moreover, no 
significant difference in the numbers of confirmed (3 versus 
3) and probable CDI relapses (2 versus 3) was found (OR, 1.5; 
95% CI, .14–16.54; P value  =  1). Of a total of 11 relapses of 
CDI, 3 were challenged by antibiotic treatment, whereas 8 (5 
in Blastocystis-positive and 3 in Blastocystis-negative treated pa-
tients) developed a relapse without antibiotics as a predisposing 
factor. The ST1 and ST3 Blastocystis sp.–positive donor fecal 
suspensions were used for the treatment of 4 and 27 rCDI pa-
tients, respectively. Treatment with feces of the Blastocystis sp. 
ST1 donor resulted in a treatment success of 75% (1/4), whereas 
the ST3 donor had a success rate of 85% (4/27; OR, 0.522; 95% 
CI, .04–6.36; P value  =  .525). In addition, no difference was 
found in the relapse rates between patients with (12.5%, 1/8) or 
without (0%, 0/8) Blastocystis sp. colonization following FMT 
Table 1. Details of Donor to Patient Transfer of Blastocystis Subtypes 1 and 3 by Fecal Microbiota Transplantation



























A ST1 25.13 119 1 Neg 21 Neg n/a n/a No
A ST1 23.57 199 2 Neg 21 Pos 25.05 ST1 Yes
B ST3 24.19 43 3 Neg 20 Pos 22.28 ST3 Yes
B ST3 20.16 34 4 Neg 5 Neg n/a n/a No
B n/aa n/a 66 5 Neg 18 Pos 22.57 ST3 Yes
B ST3 19.51 64 6 Neg 53 Pos 27.64 ST3 Yes
B ST3 18.95 119 7 Neg 15 Pos 27.77 ST3 Yes
B ST3 20.94 124 8 Neg 20 Neg n/a n/a No
B ST3 19.81 140 9 Neg 48 Pos 25.78 ST3 Yes
B ST3 23.21 152 10 Neg 20 Neg n/a n/a No
B ST3 21.11 255 11 Neg 31 Neg n/a n/a No
B ST3 21.68 360 12 Neg 29 Neg n/a n/a No
B ST3 21.68 376 13 Neg 23 Neg n/a n/a No
B ST3 19.96 385 14 Neg 20 Pos 23.86 ST3 Yes
B n/ab n/a 509 15 Neg 20 Neg n/a n/a No
B ST3 20.29 521 16 Neg 27 Pos 19.56 ST3 Yes
Abbreviations: Cq, cycle quantification; FMT, fecal microbiota transplantation; ID, identification; n/a, not available or not applicable; Neg, negative; Pos, positive; ST, subtypes. 
aTransplanted donor feces were not available; samples 6 days prior and 2 days post-FMT were positive with Blastocystis ST3. 
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with a donor suspension containing Blastocystis sp. (OR, 1.143; 
95% CI, .88–1.49; P value = 1).
There were 9 (8.0%, 9/113) patients who experienced a new 
episode of CDI later than 2 months after FMT, at a median of 
4  months (range 63–402  days) post-FMT. All new episodes 
could be attributed to the initiation of antibiotic treatment 
shortly before the development of CDI symptoms. The fre-
quency of development of a new initial episode of CDI was not 
statistically different in patients transferred with Blastocystis 
sp.–positive feces (9.7%, 3/31), versus Blastocystis sp.–nega-
tive feces (7.3%, 6/82; Table 2; Figure 1). Moreover, no statis-
tically significant difference in the development of a new initial 
CDI episode was found between patients transferred with ST1 
(0%, 0/4) and ST3 (11.1% 3/27; OR, 0.889; 95% CI, .78–1.02; P 
value = 1), or between patients that were demonstrably colon-
ized with Blastocystis post-FMT using Blastocystis-containing 
donor feces (12.5%, 1/8), versus those demonstrably Blastocystis 
negative post-FMT (0%, 0/8; OR, 1.143; 95% CI, .88–1.49; P 
value = 1).
Potential Side Effects Due to Newly Acquired Blastocystis sp. Colonization 
Following Fecal Microbiota Transplantation
Compared to patients treated with Blastocystis sp.–negative 
donor feces, patients treated with Blastocystis sp.–positive 
donor feces did not report significantly more bowel complaints 
(nausea, abdominal pain, or diarrhea) after 1 week, after 3 
weeks, or at the long-term follow-up (median, 35 weeks; range, 
10–143 weeks; Table 3). Moreover, no difference in side effects 
was observed in the subgroup of patients with demonstrable 
Blastocystis sp. colonization after FMT. Interestingly, a signifi-
cant difference towards an improvement of the self-evaluated 
defecation pattern was observed at long-term follow-up in pa-
tients receiving Blastocystis sp.–positive donor feces (Table 3).
DISCUSSION
Healthy stool donors colonized with Blastocystis sp. are usu-
ally excluded from FMT donorship [21–26], though the 
enteropathogenicity of Blastocystis sp. remains debatable [7]. 
Through a combination of PCR and subtyping techniques of 
donors and of patient pre-FMT and post-FMT fecal samples, 
the first human-to-human transmission by FMT of Blastocystis 
sp. ST1 and ST3 was described. This transmission did not 
Table 2. Follow-Up of Recurrent Clostridioides difficile Infection Fecal 
Microbiota Transplantation Treatment Success of Patients Transferred 









[95% CI], P value
FMT success rate 83.9% (26/31) 92.7% (76/82) 0.411 [.12, 1.46], 
P value = .159
Relapses of CDI 16.1% (5/31) 7.3% (6/82) 2.436 [.69, 8.65], 
P value = .159
New CDI episode, 
>2 months after 
FMT
9.7% (3/31) 7.3% (6/82) 1.357 [.32, 5.80],  
P value = .704
CDI event: relapse 
or new episode
25.8% (8/31) 14.6% (12/82) 2.029 [.74, 5.88],  
P value = .165
Percentages and final ORs with 95% CIs of the FMT treatment outcome between patients 
treated with Blastocystis sp.–positive versus –negative donor feces. A χ2 test or Fischer 
exact test was performed in cases of n < 5. 
Abbreviations: CDI, Clostridioides difficile infection; CI, confidence interval; FMT, fecal mi-
crobiota transplantation; OR, odds ratio. 
Figure 1. Kaplan-Meier curve of CDI event-free survival in patients post-FMT who were treated with Blastocystis sp.–positive versus Blastocystis sp.–negative fecal sus-
pensions. CDI-free survival is defined as survival without a relapse (<2 months post-FMT) or new CDI infection (>2 months post-FMT) within 2 years (104 weeks) after FMT. 
Follow-up data exceeding 2 years were censored at 104 weeks. Patients suffering from a new CDI event after 104 weeks were counted as having no CDI event. Abbreviations: 
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influence the success rate of the FMT to treat rCDI. More im-
portantly, it did not result in gastrointestinal symptomatology 
of the recipients.
Symptoms attributed to Blastocystis sp. infection that have 
been described in anecdotal case reports, series, and retrospec-
tive cohorts include nausea, anorexia, abdominal pain, flatu-
lence, and acute or chronic diarrhea [8]. The high prevalence 
of Blastocystis sp. colonization in healthy individuals suggests 
that Blastocystis sp. does not harm most hosts. As Blastocystis 
consists of 17 subtypes, initially the idea was raised that the 
subtype correlated with pathogenicity [30]. Numerous, globally 
performed studies comparing the subtypes of Blastocystis could 
not confirm a consistent correlation and could not explain the 
pathogenicity in some patients [30]. Currently, it is mostly ac-
knowledged that Blastocystis sp. may colonize many hosts, but 
the infection’s potential depends on the interplay between the 
virulence of the parasite, the number of infecting parasites 
present, the duration of infection (acute versus chronic), and 
host factors like genetics, immune competence, or gut micro-
biota composition [3, 4, 20, 30, 31]. The 2 identified subtypes 
in this study, ST1 and ST3, are the most commonly found sub-
types in Europe and the Netherlands [3]. In a Dutch study in 
which the stool samples of 442 patients were evaluated by rou-
tine parasitological examination, 107 (24%) stool samples con-
tained Blastocystis sp., of which 40% had Blastocystis ST3 and 
21% had Blastocystis ST1 [3]. The sustained colonization with 
Blastocystis ST1 and ST3 observed in 50% (median, 20.5 days) 
of Blastocystis-transferred patients in this study did not result 
in gastrointestinal symptomatology, as determined by patient 
follow-up questionnaires. In contrast, these Blastocystis sp.-
transferred patients evaluated their defecation pattern as being 
significantly better post-FMT, compared to patients receiving 
Blastocystis sp.–negative donor feces.
Unfortunately, a human challenge model to study the pre-
sumed enteropathogenicity of Blastocystis sp. has not been 
described [7]. In our study, the transfer of Blastocystis sp. was 
accompanied by a healthy donor microbiota. This may not re-
flect the effects of Blastocystis sp. transfers from individuals with 
intestinal complaints or a disturbed microbiota to individuals 
with a healthy microbiota. Interestingly, Blastocystis sp. may not 
be able to maintain itself in a dysbiotic rCDI microbiota, since 
we found that none of the rCDI patients carried Blastocystis sp. 
pre-FMT. Low Blastocystis sp. colonization rates in diseased 
individuals were previously also reported in patients with ac-
tive inflammatory bowel disease or hepatic encephalopathy [4, 
13, 14, 32]. These diseased individuals and rCDI patients have 
a perturbed gut microbiota in common. Whether the associ-
ation between a perturbed microbiota and low Blastocystis sp. 
colonization results from an absence of Blastocystis sp. or from 
the inability of Blastocystis to colonize and sustain itself in a 
dysbiotic gut microbiota composition is an interesting question 
that merits further research.
In this study, the importance of performing appropriate 
Blastocystis sp. diagnostics is shown. The NDFB used microscopy 
on unfixed material and used Ridley-Allen sedimentation to de-
tect Blastocystis sp., in contrast to the more superior techniques, 
which use microscopy on 2 sodium acetate formalin-fixated 
stool samples or molecular detection of a single stool sample 
[3]. Blastocystis sp. colonization of the donors or patients was, 
therefore, defined by positive PCR, irrespective of microscopic 
findings. Post-FMT stool samples with a positive Blastocystis sp. 
PCR were taken more than 2 weeks post-FMT. Together with 
the relatively low cycle quantification values (high load) found 
in these rCDI patients post-FMT, this suggests actual Blastocystis 
colonization instead of Blastocystis passage after FMT.
There is no consensus among FMT centers and stool banks 
about Blastocystis sp. screening of donors, though published 
guidelines still recommend screening, especially for immuno-
compromised patients [24]. Many centers do not screen for 
Blastocystis sp. and, according to a recent systemic review, only 
Table 3. Potential Side Effects Due to Newly Acquired Blastocystis sp. Infections After Fecal Microbiota Transplantation
Side Effect
FMT With Blastocystis sp.–Negative  
Donor, n = 82
FMT With Blastocystis sp.–Positive  
Donor, n = 31
Blastocystis sp. Colonized  
Post-FMT, n = 8a
Week 1 Weeks 2 + 3 LTFU Week 1 Weeks 2 + 3 LTFU Week 1 Weeks 2 + 3 LTFU 
Nausea, % yesa 11.0% (9/69) 12.2% (10/70) 35.0% (7/20) 13.0% (3/23) 3.2% (1/23) 12.5% (2/16) 0.0% (0/8) 0.0% (0/8) 0.0% (0/3)
Abdominal pain, % yesb 22.0% (18/70) 18.3% (15/71) 27.8% (5/18) 34.8% (8/23) 16.1% (5/23) 25.0% (3/12) 25.0% (2/8) 12.5% (1/8) 33.3% (1/3)
Diarrheab 32.9% (23/70) 22.0% (18/70) 35.0% (7/20) 26.1% (6/23) 26.1% (6/23) 25.0% (4/16) 0.0% (0/8) 37.5% (3/8) 33.3% (1/3)
Defecation pattern
 Improved n/a 16.1% (9/56) 17.6%c (3/17) n/a 13.6% (3/22) 53.8%c (7/13) n/a 12.5% (1/8) 33.3% (1/3)
 Similar n/a 67.9% (38/56) 58.8%c (10/17) n/a 68.2% (15/22) 38.5%c (5/13) n/a 62.5% (5/8) 66.7% (2/3)
 Worsened n/a 16.1% (9/56) 23.5%c (4/17) n/a 18.2% (4/22) 7.7%c (1/13) n/a 25.0% (2/8) 0.0% (0/3)
The LTFU median duration was 35 weeks, and the range was 10–143 weeks. 
Abbreviation: FMT, fecal microbiota transplantation; LTFU, long-term follow-up. 
aA subgroup of patients receiving Blastocystis sp.–positive fecal suspensions with proven intestinal colonization of Blastocystis sp. post-FMT.
bPrevalences of nausea, abdominal pain, or diarrhea were not significantly different between the groups, as tested with either a χ2 or Fischer exact test in cases of n < 5.
cA statistically significant difference in the self-evaluated defecation pattern at LTFU between patients that received Blastocystis sp.–positive versus Blastocystis sp.–negative donor feces, 
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14.5% of 168 studies reported specific Blastocystis sp. screening 
[33]. In addition, the method of screening for ova and para-
sites was often not stated [21–26]. Consequently, we assume 
that a substantial number of patients has received FMT treat-
ment for rCDI or other diseases in experimental settings, with 
cotransplantation with Blastocystis sp.
Our study is the first study that indicates that Blastocystis sp. 
transmission does not result in gastrointestinal symptoms in re-
cipients. In the setting of rCDI, the transmission of Blastocystis 
ST1 and ST3 via FMT did not result in a significant decrease in 
the efficacy of FMT, although there was a nonsignificant trend 
towards an increased rate of CDI events (both relapses and 
new episodes) in patients treated with Blastocystis sp.–positive 
donors (8/31) versus Blastocystis sp.–negative donors (12/82). 
Interestingly, this contrasts with expected outcomes that could 
have extrapolated from recent metagenomic studies, in which 
Blastocystis sp. is correlated with a more diverse and healthier 
microbiota, a general prerequisite of a good donor [4, 15–20]. In 
a large cohort of 1106 healthy Flemish individuals, Blastocystis 
sp. carriership was associated with higher microbial diversity, 
richness, and composition. Tito et  al [4] found that the most 
common subtypes in Europe—ST1, ST2, ST3, and ST4—were 
all associated with higher diversity, though ST1 and ST3 (which 
were identified in our study) had lower diversity increases than 
ST2 and ST4. For FMT treatment of rCDI, super donors have 
not been detected [34, 35] and all donors display a high cure 
rate, of around 85% [21]. The role of super-donors could play a 
more significant role in possible future FMT indications other 
than rCDI, such as ulcerative colitis, metabolic syndrome, the 
eradication of multidrug resistant organisms, or hepatic en-
cephalopathy [4, 36, 37].
In this study, only the transfer of Blastocystis ST1 or ST3 was 
studied. To assess the contribution of Blastocystis sp. transfers 
to FMT success, it is important to include microbiota data of 
donors and patients, other subtypes of Blastocystis, and longer-
term follow-up, as colonization has been described for up to 
6–10  years [38]. An important limitation of this study is vol-
untary reporting by the treating physicians of late CDI relapses 
(after 3 weeks) or new CDI episodes (after 2  months) to the 
NDFB. However, physicians had a low threshold to contact the 
NDFB, since an excellent relationship was developed during 
the entire process of the FMT request and treatment of the patient.
In conclusion, to the best of our knowledge we demonstrate 
the first transmission of Blastocystis ST1 and ST3 from donor to 
recipient via FMT without the development of gastrointestinal 
symptoms. This study is an important step towards a possible 
exemption of Blastocystis sp. (ST1 and ST3) as a donor exclu-
sion criterion in FMT.
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